Graham Holdings Company (GHC) AGM 2026 summary

Opening remarks and agenda

• Legal disclaimer highlighted forward-looking statements and associated risks.

• Meeting agenda included formal proceedings, operational updates, director elections, executive compensation vote, and Q&A.

• Introduction of board nominees and independent auditors.

Financial performance review

• 2025 revenue grew 6% in Q1 2026, with healthcare and manufacturing gains offsetting automotive declines.

• Adjusted operating cash flow in Q1 2026 rose 28% to $113 million; 5-year CAGR for revenue and cash flow exceeded 11%.

• Kaplan led absolute growth, but its share of operating cash flow declined as other segments expanded.

• Broadcasting saw 8% revenue and 31% cash flow growth in Q1, aided by major events and political advertising.

• Healthcare division surpassed $100 million in cash flow for the first time in 2025; CSI Pharmacy grew 31% in Q1.

• Manufacturing revenue up 28% and cash flow up 38% in Q1, driven by acquisitions and expansion.

• Automotive segment faced revenue and income declines due to regional economic factors and weather events.

• Share repurchases resumed in Q1 2026, with 32,190 shares bought at an average price of $1,061.

Board and executive committee updates

• Board nominees introduced; 10 directors to be elected (7 by Class A, 3 by Class B shareholders).

• Executive compensation for 2025 submitted for advisory vote.